Investorideas.com | big ideas for the small cap investor- One of the first online investor resources providing research tools for renewable energy, water and Homeland Security Investing Search www.investorideas.com
   Member Access       Sign-up       Listings        Stock Directories       Research       Cleantech       Tech Newsletter         Headlines        Video       New Ventures   




Gunderson Capital is initiating coverage of Isis Pharmaceuticals with a rating of "Buy for the Aggressive Portfolio."

Ideas get bigger when you share them...    Repost This

February 19, 2014 (Investorideas.com Newswire) Gunderson Capital Research: Isis Pharmaceuticals Rated a “Buy for the Aggressive Portfolio- Initiation of Coverage

Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner

For a copy of the research report, go to Gunderson Capital Research: Isis Pharmaceuticals | Gunderson Capital Management

An excerpt from the report:

Maybe someday, someone will tell the story of how a plate of chocolate chip cookies created the San Diego biotech industry. And changed the world.

How in the 1960's, the wife of a San Diego state senator took chocolate chip cookies to the Sacramento king pins who thought the idea of a world class scientific university in San Diego was crazy.

But after eating the cookies, that it was great.

And how today, the University of California San Diego is square in the middle of revolution in biotechnology that includes Isis Pharmaceuticals. Isis is just one of dozens of San Diego companies all located within a glider ride of the University. All racing to make medicines better, faster, less expensive.

People who listen to the Best Stocks Now radio show every day are no stranger to Isis. I have also written about it several times.

Let's look at what they do, and how well they do it. For patients. And shareholders. And why today, this is one of our higher rated stocks on our Buy list.

Isis Pharmaceuticals – Making Sense of Antisense

Isis Pharmaceuticals (ISIS), based in Carlsbad, California, is a leader in something called “antisense technology.” It is an important breakthrough in the way we treat disease. The company has developed a drug discovery platform based on RNA-targeted technologies as opposed to traditional protein targets. RNA is an optimal drug target for the following reasons:

Pipeline

Drug Target

Partner

Phasehalfandhalf
CARDIOVASCULAR
KYNAMRO™ ApoB-100

Genzyme

Phase III
ISIS-APOCIIIRx ApoCIII

-

Phase II
ISIS-CRPRx CRP

-

Phase II
ISIS-FXIRx Factor XI

-

Phase II
ISIS-APOARx Apo(a)

-

Phase I
ISIS-FVIIRx Factor VII

-

Preclinical
ISIS-ANGPTL3Rx ANGPTL3 Preclinical
SEVERE & RARE
KYNAMRO™ ApoB-100

Genzyme

Approved
Alicaforsen ICAM-1

Atlantic

Pre-Approval
ISIS-TTRRx TTR

GSK

Phase III
ISIS-SMNRx SMN2

Biogen Idec

Phase II
ISIS-APOCIIIRx ApoCIII

-

Phase II
ATL1103 GHr

ATL

Phase II
ISIS-GCCRRx GCCR

-

Phase I
ISIS-PKKRx PKK

-

Preclinical
ISIS-DMPKRx DMPK

Biogen Idec

Preclinical
METABOLIC
ISIS-PTP1BRx PTP-1B

-

Phase II
ISIS-GCCRRx GCCR

-

Phase II
ISIS-GCGRRx GCGR

-

Phase I
ISIS-FGFR4Rx FGFR4

-

Phase I
ISIS-DGAT2Rx DGAT2

-

Preclinical
CANCER
Custirsen clusterin

Teva/OncoGenex

Phase III
ISIS-EIF4ERx eIF-4E

-

Phase II
OGX-427 Hsp27

OncoGenex

Phase II
ISIS-STAT3Rx STAT3

AstraZeneca

Phase II
ISIS-ARRx AR

AstraZeneca

Preclinical
INFLAMMATION AND OTHER
ATL1102 VLA-4

ATL

Phase II
EXC 001 CTGF

Pfizer

Phase II
iCo-007 C-raf kinase

iCo

Phase II
Plazomicin Aminoglycoside

Achaogen

Phase II
ISIS-GSK3Rx Undisclosed

GSK

Phase I
XEN701 Hepcidin

Xenon

Preclinical
RG-101 RG-101

Regulus

Preclinical
ISIS-GSK4 Rx Undisclosed

GSK

Preclinical

Source: Isis Pharmaceuticals Company Website

Read the full report here

Bill Gunderson
Gunderson Capital Management
San Diego, California
PWstreet.com
@BillGunderson

More Info:

This news is published on the Investorideas.com Newswire and its syndicated partner network

Publish Your News - Send a release
News now!

Get Free investor news and stock alerts: Sign up here

Published at the Investorideas.com Newswire - Big ideas for Global Investors

Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


Investorideas.com Newswire

Mobile Alerts - Get the Investorideas.com newswire mobile app for iPhone or Android smartphone



Free News Alerts
Email:  




TOP

Investor Ideas © 2000 - 2014 InvestorIdeas.com®, ECON

Free Investor Stock Alerts
Sign up here

login | logout | about us | contact | disclaimer / disclosure |
advertise | company profile directory | partners / links |
job search | privacy policy | trade | services | sitemap |